217 related articles for article (PubMed ID: 21791475)
1. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
Kaufmann SH; Karp JE; Litzow MR; Mesa RA; Hogan W; Steensma DP; Flatten KS; Loegering DA; Schneider PA; Peterson KL; Maurer MJ; Smith BD; Greer J; Chen Y; Reid JM; Ivy SP; Ames MM; Adjei AA; Erlichman C; Karnitz LM
Haematologica; 2011 Nov; 96(11):1619-26. PubMed ID: 21791475
[TBL] [Abstract][Full Text] [Related]
2. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA
J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
Hendrickson AE; Oberg AL; Glaser G; Camoriano JK; Peethambaram PP; Colon-Otero G; Erlichman C; Ivy SP; Kaufmann SH; Karnitz LM; Haluska P
Gynecol Oncol; 2012 Feb; 124(2):210-5. PubMed ID: 22047770
[TBL] [Abstract][Full Text] [Related]
4. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
[TBL] [Abstract][Full Text] [Related]
5. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Richardson PG; Chanan-Khan AA; Lonial S; Krishnan AY; Carroll MP; Alsina M; Albitar M; Berman D; Messina M; Anderson KC
Br J Haematol; 2011 Jun; 153(6):729-40. PubMed ID: 21534941
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Vaishampayan UN; Burger AM; Sausville EA; Heilbrun LK; Li J; Horiba MN; Egorin MJ; Ivy P; Pacey S; Lorusso PM
Clin Cancer Res; 2010 Jul; 16(14):3795-804. PubMed ID: 20525756
[TBL] [Abstract][Full Text] [Related]
7. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.
Richardson PG; Chanan-Khan AA; Alsina M; Albitar M; Berman D; Messina M; Mitsiades CS; Anderson KC
Br J Haematol; 2010 Aug; 150(4):438-45. PubMed ID: 20618337
[TBL] [Abstract][Full Text] [Related]
8. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
Richardson PG; Badros AZ; Jagannath S; Tarantolo S; Wolf JL; Albitar M; Berman D; Messina M; Anderson KC
Br J Haematol; 2010 Aug; 150(4):428-37. PubMed ID: 20618338
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
Mesa RA; Loegering D; Powell HL; Flatten K; Arlander SJ; Dai NT; Heldebrant MP; Vroman BT; Smith BD; Karp JE; Eyck CJ; Erlichman C; Kaufmann SH; Karnitz LM
Blood; 2005 Jul; 106(1):318-27. PubMed ID: 15784732
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
Karp JE; Thomas BM; Greer JM; Sorge C; Gore SD; Pratz KW; Smith BD; Flatten KS; Peterson K; Schneider P; Mackey K; Freshwater T; Levis MJ; McDevitt MA; Carraway HE; Gladstone DE; Showel MM; Loechner S; Parry DA; Horowitz JA; Isaacs R; Kaufmann SH
Clin Cancer Res; 2012 Dec; 18(24):6723-31. PubMed ID: 23092873
[TBL] [Abstract][Full Text] [Related]
11. Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations.
Burris HA; Berman D; Murthy B; Jones S
Cancer Chemother Pharmacol; 2011 May; 67(5):1045-54. PubMed ID: 20652703
[TBL] [Abstract][Full Text] [Related]
12. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
Erlichman C
Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.
Lancet JE; Gojo I; Burton M; Quinn M; Tighe SM; Kersey K; Zhong Z; Albitar MX; Bhalla K; Hannah AL; Baer MR
Leukemia; 2010 Apr; 24(4):699-705. PubMed ID: 20111068
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
Schenk E; Hendrickson AE; Northfelt D; Toft DO; Ames MM; Menefee M; Satele D; Qin R; Erlichman C
Invest New Drugs; 2013 Oct; 31(5):1251-6. PubMed ID: 23543109
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.
Alexander TB; Lacayo NJ; Choi JK; Ribeiro RC; Pui CH; Rubnitz JE
J Clin Oncol; 2016 Dec; 34(34):4094-4101. PubMed ID: 27507877
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.
Pedersen KS; Kim GP; Foster NR; Wang-Gillam A; Erlichman C; McWilliams RR
Invest New Drugs; 2015 Aug; 33(4):963-8. PubMed ID: 25952464
[TBL] [Abstract][Full Text] [Related]
17. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.
Schenk EL; Koh BD; Flatten KS; Peterson KL; Parry D; Hess AD; Smith BD; Karp JE; Karnitz LM; Kaufmann SH
Clin Cancer Res; 2012 Oct; 18(19):5364-73. PubMed ID: 22869869
[TBL] [Abstract][Full Text] [Related]
18. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Maddocks K; Hertlein E; Chen TL; Wagner AJ; Ling Y; Flynn J; Phelps M; Johnson AJ; Byrd JC; Jones JA
Leuk Lymphoma; 2016 Sep; 57(9):2212-5. PubMed ID: 26764527
[No Abstract] [Full Text] [Related]
20. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
